COVID-19 and kidney transplantation: Results from the TANGO International Transplant Consortium

Cravedi et al., American Journal of Transplantation, doi:10.1111/ajt.16185

Cravedi et al., COVID-19 and kidney transplantation: Results from the TANGO International Transplant Consortium, American Journal of Transplantation, doi:10.1111/ajt.16185

Jul 2020 Source PDF

Twitter
Facebook

All Studies Meta

Analysis of 144 hospitalized kidney transplant patients showing HCQ mortality HR 1.53, p = 0.17. Subject to confounding by indication. This study is excluded in the after exclusion results of meta analysis: substantial unadjusted confounding by indication likely.

Important missing comments or errors? Let us know.

risk of death, 53.0% higher, RR 1.53, p = 0.17, treatment 36 of 101 (35.6%), control 10 of 43 (23.3%).

Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates

Cravedi et al., 10 Jul 2020, retrospective, USA, peer-reviewed, mean age 60.0, 25 authors, average treatment delay 6.0 days.

All Studies Meta Analysis Submit Updates or Corrections

This Paper HCQ All

COVID-19 and kidney transplantation: Results from the TANGO International Transplant Consortium

Paolo Cravedi, Suraj S Mothi, Yorg Azzi, Meredith Haverly, Samira S Farouk, María J Pérez-Sáez, Maria D Redondo-Pachón, Barbara Murphy, Sander Florman, Laura G Cyrino, Monica Grafals, Sandheep Venkataraman, Xingxing S Cheng, Aileen X Wang, Gianluigi Zaza, Andrea Ranghino, Lucrezia Furian, Joaquin Manrique, Umberto Maggiore, Ilaria Gandolfini, Nikhil Agrawal, Het Patel, Enver Akalin, Leonardo V Riella

American Journal of Transplantation, doi:10.1111/ajt.16185

Kidney transplant recipients may be at a high risk of developing critical coronavirus disease 2019 (COVID-19) illness due to chronic immunosuppression and comorbidities. We identified hospitalized adult kidney transplant recipients at 12 transplant centers in the United States, Italy, and Spain who tested positive for COVID-19. Clinical presentation, laboratory values, immunosuppression, and treatment strategies were reviewed, and predictors of poor clinical outcomes were determined through multivariable analyses. Among 9845 kidney transplant recipients across centers, 144 were hospitalized due to COVID-19 during the 9-week study period. Of the 144 patients, 66% were male with a mean age of 60 (±12) years, and 40% were Hispanic and 25% | 3141 CRAVEDI Et Al.

D I SCLOS U R E The authors of this manuscript have no conflicts of interest to disclose as described by the American Journal of Transplantation.

References

Akalin, Azzi, Bartash, Covid-19 and kidney transplantation, N Engl J Med

Alberici, Delbarba, Manenti, A single center observational study of the clinical characteristics and short-term outcome of 20 kidney transplant patients admitted for SARS-CoV2 pneumonia, Kidney Int

Becker, Nylen, White, Muller, Snider, Clinical review 167: procalcitonin and the calcitonin gene family of peptides in inflammation, infection, and sepsis: a journey from calcitonin back to its precursors, J Clin Endocrinol Metab

Beigel, Tomashek, Dodd, Remdesivir for the treatment of Covid-19 -preliminary report, N Engl J Med, doi:10.1056/NEJMoa2007764

Bhatraju, Ghassemieh, Nichols, Covid-19 in critically ill patients in the seattle region -case series, N Engl J Med

Boulware, Pullen, Bangdiwala, A randomized trial of hydroxychloroquine as postexposure prophylaxis for Covid-19, N Engl J Med, doi:10.1056/NEJMoa2016638

Cao, Wang, Wen, A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19, N Engl J Med

Cummings, Baldwin, Abrams, Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study, Lancet

Dandona, Nix, Wilson, Procalcitonin increase after endotoxin injection in normal subjects, J Clin Endocrinol Metab

Diao, Wang, Feng, Human kidney is a target for novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, doi:10.1101/2020.03.04.20031120

Farkash, Wilson, Jentzen, Ultrastructural evidence for direct renal infection with SARS-CoV-2, J Am Soc Nephrol, doi:10.1681/ASN.2020040432

Fernández-Ruiz, Andrés, Loinaz, COVID-19 in solid organ transplant recipients: a single-center case series from Spain, Am J Transplant

Geleris, Sun, Platt, Observational study of hydroxychloroquine in hospitalized patients with Covid-19, N Engl J Med

Hirsch, Ng, Ross, Acute kidney injury in patients hospitalized with COVID-19, Kidney Int

Huang, Wang, Li, Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, Lancet

Kim, Won, Kee, Jung, Jang, Combination therapy with lopinavir/ritonavir, ribavirin and interferon-alpha for Middle East respiratory syndrome, Antivir Ther

Maruna, Nedelnikova, Gurlich, Physiology and genetics of procalcitonin, Physiol Res

Metlay, Waterer, Treatment of community-acquired pneumonia during the coronavirus disease 2019 (COVID-19) pandemic, Ann Intern Med, doi:10.7326/M20-2189

Muller, Becker, Procalcitonin: how a hormone became a marker and mediator of sepsis, Swiss Med Wkly

Nair, Jandovitz, Hirsch, COVID-19 in kidney transplant recipients, Am J Transplant

Pereira, Mohan, Cohen, COVID-19 in solid organ transplant recipients: initial report from the US epicenter, Am J Transplant

Richardson, Hirsch, Narasimhan, Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City Area, JAMA

Tang, Li, Wang, Sun, Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia, J Thromb Haemost

Wadhera, Wadhera, Gaba, Variation in COVID-19 hospitalizations and deaths across New York City Boroughs, JAMA

Wang, Zhang, Du, Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial, Lancet

Xu, Han, Li, Effective treatment of severe COVID-19 patients with tocilizumab, Proc Natl Acad Sci

Ye, Wang, Mao, The pathogenesis and treatment of the `Cytokine Storm' in COVID-19, J Infect

Zhou, Yu, Du, Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study, Lancet

Late treatment
is less effective

Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.

Submit